What Merck Canada does

Merck Canada Inc. is the Canadian subsidiary of Merck & Co., Inc. (NYSE: MRK), headquartered in Kirkland, Quebec, and operating under the MSD brand outside the United States and Canada. The company develops, markets, and distributes a portfolio of proprietary biopharmaceutical products in Canada across four therapeutic areas: oncology (KEYTRUDA pembrolizumab, including the new subcutaneous KEYTRUDA SC formulation), vaccines (GARDASIL 9 for HPV, CAPVAXIVE 21-valent pneumococcal conjugate vaccine, ENFLONSIA clesrovimab for RSV), infectious diseases (HIV regimens including ISENTRESS and DELSTRIGO), and specialty therapeutics (WINREVAIR for pulmonary arterial hypertension). The company also operates Merck Animal Health in Canada and supports products via the MERCK CARE, MERCK FOR U, and MYCHOICE patient assistance programs that reduce affordability barriers across oncology, specialty, and HIV therapies.

Merck Canada employs approximately 635 people and is one of Canada's top R&D investors, with $90 million deployed in 2022 alone and cumulative R&D investment exceeding $1.6 billion since 2000. Revenue is generated through product sales to healthcare professionals via field sales and pharmacy distribution, public drug formularies following pan-Canadian Pharmaceutical Alliance (pCPA) negotiations, and provincial public immunization programs (CAPVAXIVE in Quebec and Saskatchewan). The Ontario pharmacy scope expansion effective July 2026 will broaden vaccine administration through retail pharmacies. Customer-facing infrastructure includes the askmerck.ca medical information portal, the merckorders.ca ordering system, and dedicated patient support program call centers. The company also operates the Merck Digital Sciences Studio (MDSS) accelerator in Montréal, investing in biopharma startups developing AI solutions, biologics R&D platforms, and 3D translational disease models.

Recent strategic activity has centered on indication expansion and reimbursement rollout for the core franchise. KEYTRUDA secured Health Canada approval for platinum-resistant ovarian cancer (May 2026) and a subcutaneous formulation (February 2026); ENFLONSIA received Health Canada approval for RSV prevention in infants (February 2026); WINREVAIR secured pCPA agreement and listings across BC, NIHB, Nova Scotia, Quebec, and VAC (November 2025 – March 2026); and CAPVAXIVE was added to Quebec and Saskatchewan public immunization programs (November – December 2025). Leadership transitioned during this period, with David D. Jones assuming the Managing Director role following the departure of AnnA Van Acker. The company partners with CQDM, Centech, the Merck Global Health Innovation Fund, The Venture Collective, and MaRS to support innovation, Indigenous student scholarships, and lung cancer initiatives.

Name

Merck Canada

Legal name

Merck Canada Inc.

Website

https://merck.ca

Company type

Public

Operating status

Operating

Headcount range

251–500 employees

Short description

Merck Canada develops, markets, and distributes proprietary biopharmaceutical products in Canada across oncology (KEYTRUDA), vaccines (GARDASIL 9, CAPVAXIVE, ENFLONSIA), pulmonary health (WINREVAIR), HIV, and animal health, serving patients, healthcare professionals, and provincial and federal public drug programs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

akta.pro secondary industries

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Biopharmaceutical medicines
• Oncology therapeutics
• Human vaccines
• Animal health products
• Patient support programs

Headquarters

HQ city

Kirkland

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Products: Sale of prescription pharmaceutical products including KEYTRUDA, WINREVAIR, and other branded medications through healthcare providers and pharmacies.
2. Vaccines: Sale of vaccines including GARDASIL 9, CAPVAXIVE, ENFLONSIA for prevention of various diseases through public and private channels.
3. Patient Support Programs: Patient assistance programs supporting access to medications including MERCK CARE Oncology, MERCK CARE Specialty, MERCK FOR U, and co-pay card programs.
4. Animal Health: Merck Animal Health products for veterinary use.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Merck Canada develops, markets, and distributes prescription pharmaceuticals, vaccines, and animal health products across four therapeutic areas: oncology (KEYTRUDA anti-PD-1 therapy), vaccines (GARDASIL 9, CAPVAXIVE, ENFLONSIA), infectious diseases, and cardio-metabolic disorders. The company also operates patient support programs (MERCK CARE, MYCHOICE, FOR U), an innovation accelerator (Merck Digital Sciences Studio), and medical information services for healthcare professionals across Canadian provinces and territories.

Product overview

Merck Canada is a biopharmaceutical company operating as MSD outside the United States and Canada. The company's product portfolio spans oncology (KEYTRUDA®), vaccines (GARDASIL®9, CAPVAXIVE®, ENFLONSIA®), pulmonary health (WINREVAIR®), and animal health. Beyond pharmaceuticals, Merck Canada offers patient support programs including MERCK CARE™ (Oncology, Testing Assistance, Specialty, PHC, Integrate), MERCK MYCHOICE™ co-pay cards, and MERCK FOR U™ patient assistance for HIV medications. The company also operates the Merck Digital Sciences Studio (MDSS) innovation accelerator in Montréal supporting biopharma startups. Merck employs approximately 635 people in Canada with R&D investments totaling over $90 million in 2022 and over $1.6 billion since 2000, based in Kirkland, Quebec.

Differentiator

Problem solved

Functional benefit

Brands

• Merck Care: Patient support programs including MERCK CARE Oncology Program, Testing Assistance Program, Specialty Program, Primary & Hospital Compassionate Program, and MERCK CARE Integrate Patient Support Program
• Merck Digital Sciences Studio (MDSS)
• Merck Care Oncology Program
• Merck MYCHOICE Program
• Merck For U

Products and services

• KEYTRUDA (pembrolizumab) Anti-PD-1 monoclonal antibody therapy for cancer treatment that works by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, activating T lymphocytes to help detect and fight tumor cells. Used across multiple cancer indications in oncology practice.
• KEYTRUDA SC (pembrolizumab injection) Subcutaneous formulation of pembrolizumab using berahyaluronidase alfa technology to facilitate subcutaneous delivery. Provides equivalent pembrolizumab exposure to the IV formulation with reduced chair time, enabling 790mg subcutaneous administration every six weeks versus 400mg IV.
• GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) 9-valent recombinant HPV vaccine for prevention of certain HPV-related cancers and diseases. Indicated for individuals 9 through 45 years of age for prevention of infection and diseases caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
• CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) 21-valent pneumococcal conjugate vaccine for active immunization preventing invasive pneumococcal disease (sepsis, meningitis, bacteremic pneumonia, pleural empyema, bacteremia) caused by Streptococcus pneumoniae serotypes. Approved for adults 18 years and older.
• ENFLONSIA (clesrovimab) Monoclonal antibody providing RSV (respiratory syncytial virus) prevention for up to five months in newborns and infants born during or entering their first RSV season. Delivered as a single intramuscular injection based on CLEVER and SMART clinical trial results.
• WINREVAIR (sotatercept) First-in-class treatment for pulmonary arterial hypertension (PAH) targeting novel pathways beyond standard PAH therapy. Indicated in combination with standard PAH therapy for adults with World Health Organization (WHO) Group 1 PAH and Functional Class II, III or IV.
• Merck Animal Health Products Animal health pharmaceutical products and vaccines for livestock and companion animals, distributed through veterinary channels across Canada. Customer service available at 1-866-683-7838. Includes medications and biologicals for veterinary use.
• MERCK CARE Oncology Program Patient support program for KEYTRUDA (pembrolizumab) providing services and access support for eligible oncology patients through their healthcare professional. Operated in partnership with Bayshore, available Monday to Friday 8am to 8pm ET.
• MERCK CARE Integrate Patient Support Program Patient support program for WINREVAIR (sotatercept) providing services and access support for eligible PAH patients through healthcare provider enrollment. Available Monday to Friday via [email protected].
• MERCK FOR U Patient Assistance Card Co-pay card program for HIV medications including DELSTRIGO, ISENTRESS, ISENTRESS HD, and PIFELTRO, providing financial assistance for eligible patients through the [email protected] channel.
• Merck Digital Sciences Studio (MDSS) Accelerator Collaborative startup accelerator in Montréal dedicated to investing in, supporting and mentoring biopharmaceutical startups focused on digital health technologies including AI solutions for preventive health, biologics R&D platforms, and 3D translational disease models. Operated in partnership with Centech, CQDM, Merck Global Health Innovation Fund, and The Venture Collective.
• AskMerck Medical Information Portal Online portal for healthcare professionals to access medical information about Merck products, report adverse events, submit stability inquiries, and obtain product samples. Backed by Merck Canada's Medical Information Centre at 1-800-567-2594 and [email protected].

Quantifiable outcome

• R&D investment over $90 million in 2022 and more than $1.6 billion since 2000
• +2 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• CentechcoreStrategic or Co-development Partner · 20 June 2025Operating partner for Merck Digital Sciences Studio (MDSS) in Montreal. Centech is a nonprofit incubator and accelerator supporting high-potential technology companies, providing entrepreneurs with access to experts, mentors, industry partners, and investors.
• CQDMcoreStrategic or Co-development Partner · 20 June 2025Biopharmaceutical research consortium supporting collaborative multi-stakeholder R&D. Partner for over 16 years, supporting MDSS initiative with $900,000 Quebec government funding through Quebec Life Sciences Strategy 2022-2025.
• MaRSminorStrategic or Co-development PartnerOntario innovation hub partnered with Merck to launch Lung Cancer Innovation Challenge targeting Ontario innovators to discover solutions reducing time from diagnosis to treatment.
• Universities Canada/Universités CanadaminorImplementation/ SI/ Consulting PartnerAdministers Merck Canada Indigenous Student Scholarship program providing $5,000 CAD bursaries to up to 8 Indigenous students per year.
• Women in GovernanceminorOthersProvides parity certification evaluating criteria across all levels of organization addressing diversity in women's career advancement. Awarded Gold Level certification to Merck Canada.
• pan-Canadian Pharmaceutical Alliance (pCPA)coreStrategic or Co-development PartnerNegotiates on behalf of provinces, territories, and federal drug programs for public reimbursement. Successfully completed negotiations for WINREVAIR making it closer to public reimbursement.
• Ridgeback BiotherapyminorStrategic or Co-development PartnerCollaboration for COVID-19 therapeutic development as part of Merck's multiple pathway approach to address the pandemic.
• OncoImmuneminorStrategic or Co-development PartnerAcquired November 2020 to support COVID-19 response efforts, part of Merck's commitment to developing effective pandemic solutions.
• Innovative Medicines CanadaminorStrategic or Co-development PartnerIndustry association framework for voluntary disclosure of payments to healthcare professionals, healthcare organizations, and international travel sponsorships.
• Pulmonary Hypertension Association of CanadaminorOthersPatient advocacy organization providing perspective on PAH patient needs supporting WINREVAIR access.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Johnson & Johnson Innovative Medicine Canada: J&J Innovative Medicine Canada competes in oncology, immunology, and pulmonary hypertension — direct overlap with KEYTRUDA in oncology and WINREVAIR in PAH. Both subsidiaries engage Canadian public payers through pCPA and disease-specific patient access pathways.
• Sanofi Canada: Sanofi Canada competes across vaccines, specialty care, and rare disease — mirroring Merck Canada's vaccine channel (including RSV and pediatric programs) and immuno-oncology adjacency. Both subsidiaries run similar pCPA-led access strategies.
• Novartis Canada: Novartis Canada operates across oncology, cardio-metabolic, and immunology, with a comparable portfolio depth and field-sales GTM motion. Both compete in Canadian provincial drug formulary negotiations and on oncology patient support programs.
• Roche Canada: Roche Canada is a major oncology-led biopharmaceutical subsidiary competing with KEYTRUDA in immune checkpoint and tumor-agnostic indications, plus a parallel diagnostics franchise. Both operate through pCPA negotiations and offer patient support programs for high-cost oncology biologics.
• AbbVie Canada: AbbVie Canada operates a specialty and oncology-led portfolio and competes in immunology and oncology indications where Merck has KEYTRUDA. Both subsidiaries rely on field sales, reimbursement negotiations, and patient support programs in Canada.
• Pfizer Canada: Pfizer Canada is the Canadian subsidiary of Pfizer Inc., operating across oncology, vaccines, infectious diseases, and animal health — the same therapeutic areas as Merck Canada. Both firms compete head-to-head for national and provincial formulary listings, run pCPA negotiations, and market parallel oncology and pneumococcal vaccine portfolios in Canada.
• Bristol-Myers Squibb Canada: BMS Canada is an oncology and specialty biologics-led subsidiary directly competing with KEYTRUDA on immune checkpoint combinations and lung cancer indications. Both subsidiaries rely heavily on pCPA negotiations and patient access programs in Canada.
• Eli Lilly Canada: Eli Lilly Canada competes in oncology, cardio-metabolic, and immunology — overlapping with Merck's cardio-metabolic franchise and adjacent oncology positioning. Both firms negotiate with provincial formularies and operate patient support services for chronic specialty conditions.
• AstraZeneca Canada: AstraZeneca Canada competes in oncology, vaccines (including RSV/COVID-19 portfolios), and cardio-metabolic disorders — areas where Merck markets KEYTRUDA, ENFLONSIA, and cardio-metabolic products. Both subsidiaries follow the same provincial listing and reimbursement playbook in Canada.
• GSK Canada: GSK Canada is a vaccines, specialty, and HIV-led biopharmaceutical subsidiary that competes directly with GARDASIL 9, CAPVAXIVE, and ENFLONSIA in provincial immunization and HPV programs, and shares the same direct-to-HCP and pharmacy distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCPDHF5XAhGP_tcU6BDUfCyQ
• LinkedInlinkedin.com/company/merck-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Canada